sunitinib zentiva 37,5 mg
zentiva, k.s., Česká republika - sunitinib - 44 - cytostatica
sunitinib zentiva 25 mg
zentiva, k.s., Česká republika - sunitinib - 44 - cytostatica
sunitinib zentiva 12,5 mg
zentiva, k.s., Česká republika - sunitinib - 44 - cytostatica
sunitinib g.l. pharma 50 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - sunitinib - 44 - cytostatica
sunitinib g.l. pharma 25 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - sunitinib - 44 - cytostatica
sunitinib g.l. pharma 12,5 mg tvrdé kapsuly
g.l. pharma gmbh, rakúsko - sunitinib - 44 - cytostatica
sigletic 100 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sigletic 50 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sigletic 25 mg
zaklady farmaceutyczne polpharma sa, poľsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.